A Nanodelivery Platform Harnessing Synthetic Lethality and Efferocytosis Inhibition for Synergistically Enhanced Immunotherapy of Triple-Negative Breast Cancer.
Oct 2026· Small· pp.
e76306
· 0 citations· 25 references
Medicine
TL;DR
Findings indicate that precise molecularly targeted ICD combined with coordinated immune activation enables efficient primary tumor suppression and promotes T-cell phenotypes associated with antitumor immune memory, providing a novel paradigm for cancer immunotherapy.
Abstract
Triple-negative breast cancer (TNBC), defined by the absence of specific therapeutic targets, shows poor clinical benefit and readily develops chemoresistance, underscoring the need for therapies that couple precise tumor cell killing with robust antitumor immunity. Drug-induced immunogenic cell death (ICD) is a promising approach. However, its efficacy is curtailed by limited tumor-cell targeting with collateral immune-cell damage and by overactive efferocytosis that rapidly removes ICD-associated danger signals, thereby restricting antitumor immunity. Herein, we develop a microenvironment-responsive nanocarrier co-delivering both PLK1 inhibitor (BI6727) and TIM-3 inhibitor (ML-T7). It integrates dual-bioeffect of synthetic lethal selective ICD and whole-immuno system remodelling initiated by effective macrophage efferocytosis inhibition. In detail, the molecular hallmark differences between tumor and immune cells was utilized to provide high-quality antigens. Meanwhile, the nanotherapeutic enables serial phagocyte regulations, such as, suppressed macrophage phagocytosis, enhanced antigen recognition and phagocytosis by dendritic cells (DCs), and then alleviated T cell exhaustion. The underlying mechanism of nanotherapeutics-mediated overall immune system reprogramming was explored by transcriptional profile analyses. These findings indicate that precise molecularly targeted ICD combined with coordinated immune activation enables efficient primary tumor suppression and promotes T-cell phenotypes associated with antitumor immune memory, providing a novel paradigm for cancer immunotherapy.
Abstract Triple-negative breast cancer (TNBC), a breast cancer subset defined by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression, faces persistent clinical challenges including narrow first-line treatment choices and inferior long-term survival rates. Imm...
Jian-Quan Yang, Wen Guo, X. Pang et al.· International Journal of Nan...· 0 citations
A review elucidates the molecular insights into the detailed mechanisms of chemoresistance in DLBCL and the developments in nanomedicine as a potential model for precision lymphoma therapy.
Dan-Yang Li, Xiao-Yan Ke, Kai Hu· Biochimica et biophysica act...· 0 citations
A biomimetic nanotherapeutic that integrates single-atom iron nanocatalysts co-loaded with a CRISPR-Cas9 plasmid targeting Glutathione Peroxidase 4 (Gpx4), the key regulator of ferroptosis, and is camouflaged with a homologous cancer cell membrane to ensure precise tumor tropism and excellent biocompatibility is introd...
Yue-Mei Wang, L. Liang, Dong-Liang Huo et al.· Advances in Materials· 0 citations
The therapeutic efficacy of cancer immunotherapy is impaired by poor tumor immunogenicity and the immunosuppressive tumor microenvironment (TME), partially driven by reprogrammed adenosine metabolism in the tumor. Here, we develop degradable CRISPR/Cas9 nanoparticles to durably and precisely downregulate CD73 expressio...
Xin-Hong Sun, Yu-Jing Sang, Teng-Fei He et al.· Nature Communications· 0 citations
A tumor cell membrane-mimetic manganese-based nanoplatform for delivering immune adjuvants (MnO2-R848@CM) to synergistically enhance the efficacy of clinical radiotherapy and highlight the potential of the MnO2–R848@CM nanoplatform in advancing synergistic cancer radioimmunotherapy.
Smart nanodelivery systems can improve the in vivo stability, tumor accumulation, TAM exposure, and spatiotemporal release of immunomodulators, small-molecule inhibitors, nucleic acid therapeutics, cytokines, and macrophage immune-checkpoint modulators, thereby improving efficacy while reducing systemic toxicity.